Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia

B-cell receptor signaling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia. The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhibitor that may be better tolerated by patients who are int...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, Kerry A., Thompson, Philip A., Allan, John N., Coleman, Morton, Sharman, Jeff P., Cheson, Bruce D., Jones, Daniel, Izumi, Raquel, Frigault, Melanie M., Quah, Cheng, Raman, Rakesh K., Patel, Priti, Wang, Min Hui, Kipps, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409022/
https://www.ncbi.nlm.nih.gov/pubmed/33730844
http://dx.doi.org/10.3324/haematol.2020.272500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409022/
https://www.ncbi.nlm.nih.gov/pubmed/33730844
http://dx.doi.org/10.3324/haematol.2020.272500

Ejemplares similares